PE20230116A1 - Formulacion de anticuerpos - Google Patents
Formulacion de anticuerposInfo
- Publication number
- PE20230116A1 PE20230116A1 PE2022002199A PE2022002199A PE20230116A1 PE 20230116 A1 PE20230116 A1 PE 20230116A1 PE 2022002199 A PE2022002199 A PE 2022002199A PE 2022002199 A PE2022002199 A PE 2022002199A PE 20230116 A1 PE20230116 A1 PE 20230116A1
- Authority
- PE
- Peru
- Prior art keywords
- sequence
- seq
- region
- antibody
- buffer
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000000872 buffer Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 239000008351 acetate buffer Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Referido a una formulacion farmaceutica estable acuosa que comprende 10-100 mg/ml de un anticuerpo anti-CD47; y excipientes farmaceuticamente aceptables que comprenden un regulador en una concentracion de 5-20 mM; al menos un estabilizador, y un surfactante, en donde la formulacion tiene un pH de aproximadamente pH 4-6,5. 2. El regulador es regulador de acetato o regulador de histidina y esta presente en una concentracion de 10 a 15 mM. El anticuerpo es un anticuerpo humanizado que comprende una region HCDR1 que comprende una secuencia (sec. con num. de ident.: 1), una region HCDR2 que comprende una secuencia (sec. con num. de ident.: 2), una region HCDR3 que comprende una secuencia (sec. con num. de ident.: 3), una region LCDR1 que comprende una secuencia (sec. con num. de ident.: 4), una region LCDR2 que comprende una secuencia (sec. con num. de ident.: 5) y una region LCDR3 que comprende una secuencia (sec. con num. de ident.: 6).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005755P | 2020-04-06 | 2020-04-06 | |
| PCT/US2021/024937 WO2021206965A1 (en) | 2020-04-06 | 2021-03-30 | Antibody formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230116A1 true PE20230116A1 (es) | 2023-01-27 |
Family
ID=78022649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002199A PE20230116A1 (es) | 2020-04-06 | 2021-03-30 | Formulacion de anticuerpos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230081265A1 (es) |
| EP (1) | EP4132580A4 (es) |
| JP (2) | JP7560038B2 (es) |
| KR (1) | KR20220163447A (es) |
| CN (1) | CN115361971A (es) |
| AU (1) | AU2021251661B2 (es) |
| CA (1) | CA3179162A1 (es) |
| CO (1) | CO2022014266A2 (es) |
| CR (1) | CR20220502A (es) |
| DO (1) | DOP2022000217A (es) |
| IL (1) | IL296995A (es) |
| MX (1) | MX2022012513A (es) |
| NZ (1) | NZ792999A (es) |
| PE (1) | PE20230116A1 (es) |
| WO (1) | WO2021206965A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3442578T (pt) * | 2016-04-15 | 2022-05-19 | Univ Leland Stanford Junior | Métodos para determinar e alcançar doses terapêuticas eficazes de agentes anti-cd47 no tratamento do cancro |
| WO2023246790A1 (zh) * | 2022-06-21 | 2023-12-28 | 广东菲鹏制药股份有限公司 | 一种含抗cd47抗体或其抗原结合片段的制剂及其制备方法和应用 |
| TW202423485A (zh) * | 2022-12-08 | 2024-06-16 | 美商伊繆諾金股份有限公司 | 包含抗cd123抗體-藥物結合物及抗cd47抗體之治療組合 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2789061A1 (en) | 2010-02-26 | 2011-09-01 | Henrik Parshad | Stable antibody containing compositions |
| EP2688910B1 (en) * | 2011-03-25 | 2019-05-29 | Amgen Inc. | Anti-sclerostin antibody crystals and formulations thereof |
| CN105435222B (zh) | 2014-09-25 | 2018-05-29 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
| PT3442578T (pt) * | 2016-04-15 | 2022-05-19 | Univ Leland Stanford Junior | Métodos para determinar e alcançar doses terapêuticas eficazes de agentes anti-cd47 no tratamento do cancro |
| PL3479819T3 (pl) | 2016-06-30 | 2024-07-01 | Celltrion Inc. | Stabilny ciekły preparat farmaceutyczny |
| SG11201903521XA (en) * | 2016-10-21 | 2019-05-30 | Amgen Inc | Pharmaceutical formulations and methods of making the same |
| EP3589368A4 (en) * | 2017-02-28 | 2021-03-24 | The Board of Trustees of the Leland Stanford Junior University | ANTIFIBROTIC ACTIVITY OF CD47 BLOCKING |
| AU2018227036B2 (en) | 2017-03-01 | 2021-07-08 | Medimmune Limited | Formulations of monoclonal antibodies |
| AU2018351006B2 (en) | 2017-10-18 | 2024-08-29 | Forty Seven, LLC | Anti-CD47 agent-based ovarian cancer therapy |
| CN110538321B (zh) * | 2018-05-29 | 2023-03-10 | 江苏恒瑞医药股份有限公司 | 一种cd47抗体药物组合物及其用途 |
| US20220143180A1 (en) * | 2019-02-26 | 2022-05-12 | Innovent Biologics (Suzhou) Co., Ltd. | Formulation comprising anti-cd47 antibody, preparation method therefor and use thereof |
| US11795223B2 (en) * | 2019-10-18 | 2023-10-24 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
-
2021
- 2021-03-30 WO PCT/US2021/024937 patent/WO2021206965A1/en not_active Ceased
- 2021-03-30 EP EP21785287.0A patent/EP4132580A4/en active Pending
- 2021-03-30 CN CN202180026779.2A patent/CN115361971A/zh active Pending
- 2021-03-30 AU AU2021251661A patent/AU2021251661B2/en active Active
- 2021-03-30 CR CR20220502A patent/CR20220502A/es unknown
- 2021-03-30 IL IL296995A patent/IL296995A/en unknown
- 2021-03-30 NZ NZ792999A patent/NZ792999A/en unknown
- 2021-03-30 JP JP2022560931A patent/JP7560038B2/ja active Active
- 2021-03-30 KR KR1020227038446A patent/KR20220163447A/ko active Pending
- 2021-03-30 PE PE2022002199A patent/PE20230116A1/es unknown
- 2021-03-30 US US17/916,994 patent/US20230081265A1/en active Pending
- 2021-03-30 CA CA3179162A patent/CA3179162A1/en active Pending
- 2021-03-30 MX MX2022012513A patent/MX2022012513A/es unknown
-
2022
- 2022-10-05 CO CONC2022/0014266A patent/CO2022014266A2/es unknown
- 2022-10-05 DO DO2022000217A patent/DOP2022000217A/es unknown
-
2023
- 2023-12-14 JP JP2023211099A patent/JP2024015409A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ792999A (en) | 2025-08-29 |
| MX2022012513A (es) | 2023-01-11 |
| BR112022020136A2 (pt) | 2022-11-22 |
| AU2021251661B2 (en) | 2025-04-17 |
| IL296995A (en) | 2022-12-01 |
| JP2023520597A (ja) | 2023-05-17 |
| JP7560038B2 (ja) | 2024-10-02 |
| AU2021251661A1 (en) | 2022-11-03 |
| CA3179162A1 (en) | 2021-10-14 |
| EP4132580A4 (en) | 2024-05-08 |
| CO2022014266A2 (es) | 2022-11-08 |
| DOP2022000217A (es) | 2022-11-30 |
| JP2024015409A (ja) | 2024-02-01 |
| CR20220502A (es) | 2023-01-13 |
| EP4132580A1 (en) | 2023-02-15 |
| WO2021206965A1 (en) | 2021-10-14 |
| CN115361971A (zh) | 2022-11-18 |
| KR20220163447A (ko) | 2022-12-09 |
| US20230081265A1 (en) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230116A1 (es) | Formulacion de anticuerpos | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| NZ630885A (en) | Antibody formulation | |
| ECSP19062769A (es) | Formulación de anticuerpo monoclonal anti-vrs | |
| UY39878A (es) | Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma | |
| PE20230415A1 (es) | ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SINDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2) | |
| PE20251257A1 (es) | Formulaciones de inmunoconjugado anti-cd79b estables | |
| MY182680A (en) | Antibody formulation and therapeutic regimens | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| PE20231049A1 (es) | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso | |
| PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
| PE20212185A1 (es) | Formulacion de anticuerpos terapeuticos | |
| AR092325A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit | |
| MX2023009693A (es) | Anticuerpo anti-peptidilarginina desiminasa 4 (pad4) novedoso. | |
| PE20201494A1 (es) | Anticuerpo anti-pacap | |
| CL2024002975A1 (es) | Anticuerpo biespecífico anti-tigit y anti-pvrig, composición farmacéutica del mismo, y uso del mismo | |
| CA3256036A1 (en) | Anti-PVRIG antibodies, pharmaceutical composition and associated uses | |
| PE20221281A1 (es) | Formulaciones de anticuerpos anti-pd-l1 | |
| ZA202500116B (en) | Anti-cldn18.2 antibody, and pharmaceutical composition and use thereof | |
| AR124067A2 (es) | Formulaciones estables que comprenden un anticuerpo biespecífico para egfr / c-met | |
| AR117707A1 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| PE20230001A1 (es) | Materiales y metodos para la union de siglec-3/cd33 | |
| PE20030433A1 (es) | Formulacion liquida que comprende cetuximab | |
| AR083338A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r) |